Finally, we show that SHPRH may also serve to be a predictor of response to therapeutic agents, whereby inactivation of SHPRH is associated with better efficacy of drug therapies that operate by inducing overwhelming amounts of DNA damage to the cancer cells, providing a potential strategy for treatment of LUAD patients. Here, SHPRH is linked to cancer.